Core Insights - Bristol Myers Squibb (BMY) is positioned to continue its earnings-beat streak, having a history of exceeding earnings estimates, particularly in the last two quarters with an average surprise of 23.51% [1][3] Earnings Performance - In the last reported quarter, Bristol Myers achieved earnings of $1.80 per share, surpassing the Zacks Consensus Estimate of $1.49 per share, resulting in a surprise of 20.81% [2] - For the previous quarter, the company was expected to report earnings of $1.64 per share but delivered $2.07 per share, yielding a surprise of 26.22% [2] Earnings Estimates and Predictions - Estimates for Bristol Myers have been trending upward, influenced by its history of earnings surprises [3] - The company currently has a positive Earnings ESP of +0.43%, indicating that analysts are optimistic about its earnings prospects [6] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a strong possibility of another earnings beat in the upcoming report [6] Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [4] - The Earnings ESP metric compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [5] Future Outlook - The next earnings report for Bristol Myers is anticipated to be released on February 6, 2025 [6]

Company Overview - Bristol Myers Squibb (BMY) is expected to report a year-over-year decline in earnings with a projected EPS of $1.46, reflecting a decrease of 14.1% compared to the previous year [3] - Revenue for the quarter is anticipated to be $11.57 billion, which represents a slight increase of 0.8% from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised down by 7.02% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Bristol Myers is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +0.43%, suggesting a likelihood of beating the consensus EPS estimate [10][11] Historical Performance - In the last reported quarter, Bristol Myers exceeded the expected EPS of $1.49 by delivering $1.80, achieving a surprise of +20.81% [12] - The company has successfully beaten consensus EPS estimates in the last four quarters [13] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Qiagen (QGEN) is also expected to report earnings of $0.62 per share, reflecting a year-over-year increase of 12.7% [17] - Qiagen's revenue is projected to be $520.73 million, up 2.3% from the previous year, with an Earnings ESP of 2.76% indicating a likely earnings beat [18]

Group 1 - The article identifies 10 undervalued dividend growth stocks for further research and potential investment, emphasizing their quality scores as a basis for selection [1] - The author recommends investing in dividend growth stocks and writing options to enhance dividend income, highlighting a portfolio named DivGro that focuses on such stocks [1] - The article is part of a monthly series aimed at providing insights into dividend growth investing, stock selection, and passive income generation [1] Group 2 - The author has a beneficial long position in the shares of HSY, HRL, and VZ, indicating a personal investment interest in these stocks [2] - The article expresses the author's opinions without any compensation from companies mentioned, ensuring an unbiased perspective [2] - There is a disclaimer regarding past performance not guaranteeing future results, emphasizing the independent nature of the analysis [3]

Core Viewpoint - Many stocks, including those in the S&P 500, offer low dividend yields, averaging just 1.3%, making it challenging for income investors to generate significant returns from dividends [1] Group 1: Investment Opportunities - Bristol Myers Squibb is highlighted as a top healthcare investment with a focus on drug development, recently receiving FDA approval for Cobenfy, which could generate $7.5 billion at peak revenue, and expanding the use of Breyanzi, potentially generating $2 billion [4][5] - Target is identified as a Dividend King with over 50 consecutive years of dividend increases, currently yielding 2.9%, despite a 34% decline in share price over the past three years [6][8] - Suncor Energy, a major player in the oil and gas industry, has seen a nearly 40% increase in value over the past three years and generated CA$54.8 billion ($38.08 billion) in revenue, with a forward P/E of 14 and a dividend yield of 4.1% [9][10][11] Group 2: Financial Performance - Bristol Myers Squibb is trading at less than 9 times projected earnings for the next year, indicating potential value for investors [5] - Target has maintained flat revenue over the past three quarters but has grown earnings by over 8%, suggesting resilience despite economic headwinds [7] - Suncor's operating profit over the last 12 months was CA$9.6 billion ($6.67 billion), reflecting strong financial performance and a disciplined capital program aimed at increasing production and lowering costs [10][11]

Company Performance - Bristol Myers Squibb (BMY) closed at $60.62, reflecting a +1.59% change from the previous day's closing price, outperforming the S&P 500's daily loss of 1.46% [1] - Over the past month, BMY shares have increased by 3.45%, surpassing the Medical sector's gain of 1.84% and the S&P 500's gain of 1.08% [1] Upcoming Earnings - The company's earnings report is scheduled for February 6, 2025, with projected earnings of $1.46 per share, indicating a year-over-year decline of 14.12% [2] - Revenue is expected to reach $11.56 billion, representing a 0.76% increase compared to the same quarter last year [2] Analyst Estimates - Recent changes to analyst estimates for Bristol Myers Squibb are being closely monitored, as they often indicate shifts in near-term business trends [3] - Positive estimate revisions are interpreted as favorable signs for the company's business outlook [3] Zacks Rank and Valuation - The Zacks Rank system, which evaluates estimate changes, currently ranks Bristol Myers Squibb at 3 (Hold), with the Zacks Consensus EPS estimate having decreased by 1.61% in the past month [5] - The company has a Forward P/E ratio of 8.44, which is significantly lower than the industry average of 22.83, and a PEG ratio of 2.11 compared to the industry average of 1.36 [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Bristol Myers Squibb, has a Zacks Industry Rank of 70, placing it in the top 28% of over 250 industries [7] - Historically, the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Viewpoint - Bristol Myers Squibb identifies Alzheimer's disease as the largest market opportunity for its newly approved schizophrenia drug, Cobenfy, which is expected to generate billions in revenue [1][2]. Market Potential - Each treatment application for Cobenfy, including Alzheimer's-related psychosis, agitation, cognition, bipolar disorder, and autism, has multibillion-dollar potential, with Alzheimer's being the most significant market [2]. - There are nearly 6 million Alzheimer's patients in the U.S., with approximately half experiencing psychosis, making Cobenfy a potential first drug specifically approved for this condition [3]. Treatment Advantages - Current atypical antipsychotics used for treating Alzheimer's psychosis are not approved for this purpose and can increase mortality risk, whereas Cobenfy does not carry this risk [4]. - Alzheimer's agitation affects an estimated 60% to 70% of Alzheimer's patients, indicating a substantial need for effective treatment options [4]. Development Timeline - Bristol Myers Squibb plans to release initial late-stage trial data for Cobenfy in treating Alzheimer's-related psychosis by the end of the year, ahead of previous expectations [5]. - Phase three trials for Alzheimer's agitation, cognition, and bipolar disorder are expected to start in 2025, with autism studies commencing in 2026 [5]. Financial Projections - JPMorgan analyst estimates Cobenfy sales could reach approximately $5 billion by 2030, with peak sales potential in the $10 billion range across various treatment applications, providing significant revenue support for Bristol Myers Squibb amid patent expirations of top-selling treatments [6].

Key Points Company and Industry Information 1. **Company**: Bristol-Myers Squibb Company (NYSE:BMY) 2. **Event**: 43rd Annual J.P. Morgan Healthcare Conference 3. **Date**: January 13, 2024 4. **Time**: 10:30 AM ET 5. **Participants**: - Chris Boerner - Chairman and Chief Executive Officer of Bristol-Myers Squibb - Chris Schott - JPMorgan [1] Core Views and Arguments 1. **CEO's First Year**: Chris Boerner highlighted his first year as CEO, expressing pride in the company's accomplishments. 2. **Roadmap for Growth**: The company outlined a roadmap for a multi-year journey to reshape BMS with the goal of delivering sustained top-tier growth and driving long-term shareholder value. 3. **Sector Growth**: The company aims to be one of the fastest-growing companies in the sector by the end of the decade. 4. **Progress Update**: Boerner mentioned that the company is one year into this journey and closer to achieving its objectives. [4][5] Other Important Content 1. **Forward-Looking Statements**: Boerner mentioned that some of the statements made during the presentation would be forward-looking. 2. **Looking Forward**: Boerner expressed excitement about the discussions planned for the day. [5][3]

Company Overview - Bristol-Myers Squibb Company is participating in the 43rd Annual J.P. Morgan Healthcare Conference, with CEO Chris Boerner leading the presentation [1][2][3] - The company aims to reshape its operations with a focus on sustained top-tier growth and long-term shareholder value [5] Strategic Goals - The overarching goal is to become one of the fastest-growing companies in the sector by the end of the decade, with a multi-year roadmap laid out at the previous year's conference [5] - The company is one year into its journey towards achieving its growth objectives and is optimistic about its progress [5][4]

Collaboration Details - Bristol Myers Squibb has exercised its exclusive license option for ArsenalBio's AB-4000 series, a lead collaboration program under the multi-program agreement signed in December 2020 [1] - The collaboration aims to advance next-generation T cell therapies for the treatment of solid tumors [1] - ArsenalBio is responsible for discovering and building preclinical candidates against multiple targets, while Bristol Myers Squibb has the option to obtain an exclusive worldwide license to develop and commercialize these candidates [2] - Following the exercise of the option, Bristol Myers Squibb will be solely responsible for developing and commercializing the licensed candidates [2] - ArsenalBio remains eligible for additional milestone payments and royalties on potential commercial sales as the programs advance [3] ArsenalBio's Technology and Pipeline - ArsenalBio is a clinical-stage programmable cell therapy company focused on engineering advanced CAR T cell therapies for solid tumors [1] - The company leverages its proprietary synthetic biology toolkit, including CRISPR-based CITE (CRISPR Integration of Transgene via Electroporation), to create the AB-4000 series [5] - CITE cassettes include features such as PrimeR logic gates and shRNA cassettes to improve T cell product's ability to identify and eradicate solid tumors while limiting off-target effects [5] - ArsenalBio's clinical pipeline includes AB-2100 for kidney cancer and multiple preclinical candidates for prostate cancer and other solid tumors [4] - The company is pioneering an AI-enabled foundation model of the T cell using deep learning to accelerate target discovery and improve patient segmentation for drug development [4] Strategic Milestones - In January 2022, Bristol Myers Squibb exercised an option to initiate a new program, expanding its strategic collaboration with ArsenalBio [2] - In July 2023, Bristol Myers Squibb entered a limited co-exclusive commercial license agreement for the use of ArsenalBio's proprietary TME control technology to potentially increase CAR T therapeutic effects in a limited number of Bristol Myers Squibb cell therapy products [2] - The recent exercise of the exclusive license option for the AB-4000 series further strengthens the collaboration between the two companies [1]

Group 1: Company Performance - Bristol Myers Squibb (BMY) ended the recent trading session at $56.81, showing a -0.58% change from the previous day's closing price, which lagged behind the S&P 500's daily gain of 0.16% [1] - Over the past month, shares of Bristol Myers Squibb gained 0.28%, outperforming the Medical sector's loss of 5.31% and the S&P 500's loss of 2.7% [1] Group 2: Upcoming Earnings - The company's earnings report is scheduled for February 6, 2025, with analysts expecting earnings of $1.46 per share, indicating a year-over-year decline of 14.12% [2] - The Zacks Consensus Estimate for revenue projects net sales of $11.6 billion, reflecting a 1.05% increase from the year-ago period [2] Group 3: Analyst Estimates and Rankings - Recent changes to analyst estimates for Bristol Myers Squibb are important as they reflect the shifting dynamics of short-term business patterns [3] - The Zacks Rank system, which includes estimate changes, currently ranks Bristol Myers Squibb at 2 (Buy), with a 0.29% rise in the Zacks Consensus EPS estimate over the past month [5] Group 4: Valuation Metrics - Bristol Myers Squibb is trading at a Forward P/E ratio of 7.9, which is a discount compared to the industry average Forward P/E of 22.58 [6] - The company has a PEG ratio of 1.98, compared to the Medical - Biomedical and Genetics industry's average PEG ratio of 1.5 [6] Group 5: Industry Overview - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 64, placing it in the top 26% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]